Cat. No. : |
TNFRSF14-945H |
Product Overview : |
Recombinant human HVEM-Fc Chimera produced inInsect cellsis a 376 amino acid fusion protein containing an N-terminal domain corresponding to the extracellular region of HVEM and a C-terminal domain corresponding to residues 102 to 330 of human IgG1. |
Description : |
HVEM belongs to the TNF Receptor superfamily of transmembrane proteins and plays a role in the activation of T-cells and other lymphocytes. It is expressed in various cells and tissues including spleen, thymus, lung, macrophages, and T-cells. HVEM activation induces a signaling cascade which results in induction of transcription factors NF-kappaB and AP-1. LIGHT (TNFSF14) and TNF-beta (TNFSF1) function as the ligands for HVEM, which can also bind specifically to herpes simplex virus glycoprotein D. Soluble HVEM can act as a “receptor decoy” resulting in inhibition of the activity of the HVEM ligands, LIGHT and TNF-beta. |
Source : |
Insect cells. |
Purity : |
> 98%, by SDS-PAGE and HPLC analysis. |
Endotoxin Level : |
< 0.1 ng per μg sHVEM/Fc. |
Stabilizer : |
None. |
Formulation : |
Lyophilized. |
Biological Activity : |
Determined by its ability to neutralize 0.25 ng/ml of hTNFβ induced cytotoxicity on murine L929 cells. The expected ED50for this effect is 1.3-1.9 μg/ml of HVEM-Fc. |
Stability : |
The lyophilized protein is stable for at least 2 years from date of receipt at -20℃. Reconstituted HVEM-Fc is stable for at least 3 months when stored in working aliquots with a carrier protein at -20℃. Avoid repeated freeze-thaw cycles. |
nullValue_other : |
Cytokine-cytokine receptor interaction; Signaling in Immune system |